If your knees ache, you have probably heard that cartilage does not heal well, and the 2025 and 2026 science explains exactly why: the cells that build cartilage wear out, and no approved treatment yet rebuilds the tissue. At the same time, that same science is opening genuinely new avenues, from targeting aging cells to stem cell and growth factor research. This article walks through what researchers learned about cartilage in the last year and what it honestly means for someone considering regenerative care in Honolulu.
0.75x
lower risk of developing knee osteoarthritis with regular physical activity, per a 2025 meta-analysis
0.05 mm
average knee cartilage thickening with sprifermin in the FORWARD trial, sustained to five years
802
participants in the December 2025 meta-analysis finding exercise plus injection beats injection alone (low certainty)
Cartilage is the smooth, spongy tissue that lets joints glide, and it has no blood supply of its own, which is exactly why it repairs so poorly: the repair cells and nutrients that heal other tissues simply do not arrive. A December 2025 update on disease-modifying osteoarthritis drugs put it plainly: no intra-articular drug currently restores the cartilage matrix, and the pro-anabolic candidates that direct stem cells to become cartilage cells are still investigational. That is the honest foundation for every conversation about joint injections, and a clinic that pretends otherwise is not reading the same literature.
The most interesting shift in 2025 was the field's embrace of cellular aging, or senescence, as a driver of joint degeneration. As we age, some cartilage cells stop dividing and start leaking inflammatory signals that damage the tissue around them. The 2025 Osteoarthritis and Cartilage year in review named chondrocyte senescence a key mechanistic target, and researchers are testing senolytics, drugs that clear aging cells, and senomorphics, drugs that quiet them, including early CAR-T approaches. In November 2025, a Stanford Medicine study reported that blocking a master regulator of aging, which the researchers called a gerozyme, regenerated joint cartilage in mice and in human cartilage tissue. None of this is a treatment you can book yet, but it explains why joint care is likely to look very different in ten years.
“The 2025 cartilage biology year in review identifies chondrocyte senescence as a key mechanistic target, with senolytics, senomorphics, and CAR-T approaches among the strategies now under investigation.”
Stem cell injections for knee osteoarthritis generate the most patient interest and the most marketing, so the nuances matter. A 2025 meta-analysis of randomized trials in Frontiers in Medicine concluded that a majority of the symptomatic benefit seen after mesenchymal stem cell injections is driven by contextual and placebo effects, with only low-certainty evidence of structural benefit. A 2026 meta-analysis in Clinical Rheumatology found functional gains on some knee scores with culture-expanded, bone-marrow-derived stem cells, but no significant differences on the broader WOMAC or quality-of-life measures. The fair reading: stem cell therapy can help some people with knee osteoarthritis, its effect is smaller and less structural than many clinics claim, and high-quality patient selection is everything.
The strongest structural signal in the entire field remains sprifermin, a recombinant growth factor studied in the FORWARD trial. It produced dose-dependent thickening of knee cartilage of roughly 0.05 millimeters at the 100 microgram dose every six months, and that signal was sustained to five years of follow-up. But symptoms improved only modestly alongside it, the changes are small, and sprifermin is not yet approved. The lesson for patients: measurable cartilage change and noticeable pain relief are two different outcomes, and a treatment can deliver one without the other.
While the science races ahead, the best-evidenced joint care is the boring kind, and the 2025 and 2026 literature is unusually clear about it. A 2025 BMJ network meta-analysis found aerobic exercise produces large short- and mid-term improvements in pain and function for knee osteoarthritis. A 2025 meta-analysis in the Journal of Global Health linked regular physical activity with roughly a 0.75-fold lower risk of developing knee osteoarthritis in the first place. And a December 2025 meta-analysis found that combining structured exercise with intra-articular injections may improve pain, function, and quality of life more than injections alone, though the certainty of that evidence is low. Exercise, education, and weight management remain the foundation, and injections, when appropriate, work best on top of them, not instead of them.
For a patient in Honolulu, the takeaway is both honest and hopeful. No stem cell or PRP injection is a proven cartilage regenerator, and a clinic should say so. But the toolkit for keeping active joints healthy is real: proper diagnosis, guided exercise and weight management, and regenerative options like autologous stem cell therapy and PRP for selected cases where they are genuinely supported. The science on senescence is also a reminder that the field is moving, which is exactly why our educational library is updated as new evidence lands.
A note from the clinic
At Aloha Stem Cell in Honolulu we read the 2025 and 2026 cartilage science closely, and we translate it into honest guidance: what can help, what is still experimental, and what will not work no matter how it is marketed. Your consultation starts with a careful evaluation and a straight conversation about what the evidence supports for your joints. Call (808) 593-2525 or book a consultation to start that conversation.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.